
[EPISODE 24] Dr. David Berkowitz Talks Enzymes, Radiation, And The Lincoln Marathon
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With
BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With
BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
Vice President & General Manager, BioAgilytix San Diego
President, 360biolabs
Vice President, Business Development, BioAgilytix Europe
Vice President & General Manager, BioAgilytix Boston
Vice President, Quality Assurance & Corporate Compliance
Vice President, Business Development
General Manager, BioAgilytix Europe
Vice President & General Manager, BioAgilytix Durham
Executive Vice President, Commercial, 360biolabs
Chairman and Chief Executive Officer
Chief Scientific Officer
Executive Vice President, Scientific Operations, 360biolabs
Chief Operating Officer
Chief Financial Officer
Vice President & General Manager, BioAgilytix Durham
Scientific Officer,
Senior Director
Scientific Officer,
Executive Director
Chief Scientific Officer
Scientific Officer,
Director
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St, Woolloongabba
Queensland, 4102, Australia
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St,Woolloongabba
Queensland, 4102, Australia
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
+61 3 9282 2184
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
+61 3 9282 2184
Copyright © 2023 BioAgilytix Labs.
All rights reserved.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
5927 S. Miami Blvd. Suite 100
Morrisville, NC 27703
919-381-6097
Fax 919-381-6099
1320 Soldiers Field Road
Boston, MA, 02135
Office 617-456-0700
Fax 617-456-0701
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
37 Kent St, Woolloongabba
Queensland, 4102, Australia
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Copyright © 2023 BioAgilytix Labs.
All rights reserved.
Terms of Use | Privacy Notice
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
5927 S. Miami Blvd. Suite 100
Morrisville, NC 27703
919-381-6097
Fax 919-381-6099
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
37 Kent St,Woolloongabba
Queensland, 4102, Australia
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Copyright © 2023 BioAgilytix Labs.
All rights reserved.
Edux21 Slot Server Pro Daftar Buku303 Daftar Buku303 Daftar Slot Gacor Daftar Server Kamboja Daftar Server Luar Daftar Server Thailand Daftar Server Thailand Daftar Pro Kamboja PG Soft Daftar Server Vietnam Daftar Server Myanmar Daftar Server Luar Daftar Slot Gacor Daftar Pro Kakek Daftar Slot VIP Daftar Slot Hoki Daftar Slot Hacker Daftar Slot Zeus Tips Menang Slot Daftar Pro Thailand Daftar Pro Thailand Daftar Server Thailand Daftar Sbobet88 Daftar Server Luar Daftar Slot Demo Daftar Sbobet88 Daftar Server Vietnam Slot Server Thailand Slot Server Kamboja Akun Pro Rusia Akun Pro Server Luar slot server taiwan slot server rusia slot server hongkong slot server jepang slot server china Slot Server Thailand Slot PG Soft Slot Server Thailand Slot Server Thailand Slot Server Thailand Slot Bonanza Mega Roulette Pragmatic Slot Server Kamboja Slot Server Malaysia Slot Server Macau Akun Pro Singapore Akun Pro Malaysia Slot Server Korea Akun Pro Malaysia Slot Server Hongkong Akun Pro Jepang Akun Pro Myanmar slot server thailand slot server thailand slot server filipina slot server jepang slot server malaysia slot server malaysia akun pro kamboja Slot Kamboja Slot Server Myanmar Slot Server Malaysia Slot Server Jepang Slot Server Malaysia Slot Server Malaysia Slot Demo Slot Server Luar Slot Server Luar Slot Zeus Slot PG Soft Slot Server Thailand slot server filipina slot server thailand akun pro kamboja slot server malaysia akun pro taiwan akun pro kamboja akun pro thailand akun pro taiwan akun pro malaysia akun pro jepang akun pro swiss akun pro peru akun pro vietnam slot server kamboja akun pro china slot server thailand slot server myanmar slot server vietnam slot server malaysia slot server filipina slot server jepang slot server singapore slot server spain akun pro taiwan akun pro thailand akun pro malaysia akun pro jepang akun pro swiss akun pro vietnam akun pro singapore akun pro peru akun pro china akun pro hongkong
Vice President & General Manager, BioAgilytix San Diego
Vice President, Business Development, BioAgilytix Europe
Vice President, Quality Assurance & Corporate Compliance
Vice President, Business Development
Executive Vice President, Commercial, 360biolabs
Co-founder of 360biolabs and Executive Director, Angela leads business development and future expansion activities. Angela has extensive drug discovery pharmaceutical experience and expertise in early phase drug discovery through to IND filing. With a background in virology and the combination of technical expertise and business acumen, Angela understands a client’s requirements from the initial engagement.
Chief Scientific Officer
Executive Vice President, Scientific Operations, 360biolabs
Dr. Linda Robbie Is Chief Operating Officer And Leads All Global Operations Teams To Ensure Operational Efficiency Inclusive Of Effective Resource Management And Continuous Process Improvement.
She has more than 25 years of experience with biomarker assay technologies, including 20 years of experience in scientific leadership positions. She was previously Vice President and General Manager, Boston Operations and Senior Vice President of Science and Laboratory Operations at Cambridge Biomedical, joining the BioAgilytix leadership team when the company was acquired in November 2019.
Dr. Robbie has held prior roles at Quintiles, where she was responsible for establishing the Q2 Solutions/Quintiles global assay development business from the ground up, and with Immucor, a biotechnology company engaged in the development and automation of new assays to benefit the blood transfusion industry. Dr. Robbie held a post-doctoral research fellowship in Cardiovascular Science at Harvard Medical School as a member of the distinguished research team in Dr. Peter Libby’s laboratory, and earned a Ph.D. in Immunology and Hematology from the University of Aberdeen and a BSc with Honors in Biochemistry from Heriot-Watt University in Edinburgh.Nathan Speicher is the Chief Financial Officer for BioAgilytix and is responsible for the strategy, planning and execution of the enterprise’s financial and accounting operations. He is a seasoned leader with over 16 years of experience spanning a variety of roles with a particular focus on the biopharmaceutical and pharma services sectors.
Before joining BioAgilytix, Nathan was the Chief Financial Officer for NationsBenefits, a leading supplemental benefits provider serving the managed care space and recognized as one of the fastest growing scaled healthcare assets in the US.
Previously, Nathan worked at PPD (now Thermo Fisher Scientific) where most recently he served as Chief Commercial Officer for the laboratory services business and held several other roles including Senior Vice President of Finance, where he led the company’s FP&A, Treasury, Capital Markets, and Investor Relations functions. Nathan and his team were heavily involved in the company’s 2020 initial public offering, which represents one of the largest and most successful healthcare IPOs listed on Nasdaq in over a decade. Before PPD, Nathan was the Treasurer for Acelity, a medical device company now part of 3M and earlier in his career served as a Vice President at Morgan Stanley, where he focused on raising capital for clients in the healthcare and biopharmaceutical sectors.
He earned his bachelor’s degree in Finance from the University of Connecticut.
Scientific Officer, Senior Director
Scientific Officer, Executive Director
Scientific Officer, Director
Slot Malaysia Sbobet88 Demo Slot Daftar Server Luar Daftar Server Thailand Sbobet88 Daftar Server thailand Daftar Server jepang Daftar Server myanmar Daftar Server Thailand Akun Pro Myanmar Akun Pro Jepang Akun Pro Rusia Situs Luar Negeri Slot Server Pagcor Slot Bonanza Slot Server Macau PGSlot Slot Server Kamboja Slot Server Myanmar PG Slot Slot Demo Pragmatic Slot Server Thailand Link Server Luar Slot Server Luar Slot Server Thailand Slot Server Luar Slot Server Luar Slot Server Thailand PGSlot Slot Zeus Akun Pro Jepang Slot Server Kamboja Akun Pro Peru Slot Server Kamboja Slot Server Korea Slot Server Luar Slot Server Kamboja